MX2022013963A - Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas. - Google Patents

Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.

Info

Publication number
MX2022013963A
MX2022013963A MX2022013963A MX2022013963A MX2022013963A MX 2022013963 A MX2022013963 A MX 2022013963A MX 2022013963 A MX2022013963 A MX 2022013963A MX 2022013963 A MX2022013963 A MX 2022013963A MX 2022013963 A MX2022013963 A MX 2022013963A
Authority
MX
Mexico
Prior art keywords
methods
adeno
associated virus
cross
species compatible
Prior art date
Application number
MX2022013963A
Other languages
English (en)
Spanish (es)
Inventor
Aravind Asokan
Trevor Gonzalez
Lawrence Patrick Havlik
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of MX2022013963A publication Critical patent/MX2022013963A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MX2022013963A 2020-05-05 2021-05-05 Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas. MX2022013963A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063020062P 2020-05-05 2020-05-05
PCT/US2021/030937 WO2021226267A2 (en) 2020-05-05 2021-05-05 Cross-species compatible adeno-associated virus compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022013963A true MX2022013963A (es) 2023-02-22

Family

ID=78468375

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013963A MX2022013963A (es) 2020-05-05 2021-05-05 Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.

Country Status (13)

Country Link
US (3) US12577586B2 (https=)
EP (1) EP4125977A4 (https=)
JP (1) JP7756439B2 (https=)
KR (1) KR20230029616A (https=)
CN (1) CN116096377B (https=)
AR (1) AR122013A1 (https=)
AU (1) AU2021268946A1 (https=)
BR (1) BR112022022644A2 (https=)
CA (1) CA3177869A1 (https=)
IL (1) IL297577A (https=)
MX (1) MX2022013963A (https=)
TW (1) TWI910162B (https=)
WO (1) WO2021226267A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177869A1 (en) * 2020-05-05 2021-11-11 Duke University Cross-species compatible adeno-associated virus compositions and methods of use thereof
KR20240095539A (ko) 2021-10-08 2024-06-25 디노 테라퓨틱스, 인코포레이티드 캡시드 변이체 및 이의 사용 방법
US20260055144A1 (en) * 2022-08-24 2026-02-26 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
WO2024168089A2 (en) * 2023-02-07 2024-08-15 Duke University Compositions comprising aavs and methods for treating gastrointestinal diseases
EP4661916A1 (en) * 2023-02-08 2025-12-17 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome
WO2024191778A1 (en) 2023-03-10 2024-09-19 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
AU2024242227A1 (en) * 2023-03-31 2025-11-13 Duke University Compositions comprising brain-tropic aavs and methods of use thereof
AU2024332181A1 (en) 2023-08-31 2026-02-12 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof
TW202545971A (zh) 2024-02-08 2025-12-01 美商戴諾治療公司 殼體多肽及其使用方法
WO2025250454A1 (en) * 2024-05-28 2025-12-04 University Of Rochester Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
WO2026064442A2 (en) 2024-09-18 2026-03-26 Dyno Therapeutics, Inc. Capsid polypeptides and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
EP2345731B1 (en) * 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP2018421B1 (en) * 2006-04-28 2012-12-19 The Trustees of the University of Pennsylvania Scalable production method for aav
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
EP3003391B1 (en) 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EP3151866B1 (en) * 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
US11905312B2 (en) 2017-02-15 2024-02-20 The University Of North Carolina At Chapel Hill Methods and compositions for gene transfer across the vasculature
JP2020510424A (ja) * 2017-02-28 2020-04-09 アドヴェラム バイオテクノロジーズ, インコーポレイテッド 改変aavカプシドおよびその使用
WO2018170015A1 (en) 2017-03-14 2018-09-20 The Regents Of The University Of California Engineering crispr cas9 immune stealth
US10550405B2 (en) 2017-03-15 2020-02-04 The University Of North Carolina At Chapel Hill Rational polyploid adeno-associated virus vectors and methods of making and using the same
NZ756587A (en) * 2017-03-15 2025-12-19 Univ North Carolina Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
US20210214749A1 (en) 2018-05-16 2021-07-15 Voyager Therapeutics, Inc. Directed evolution
CA3114175A1 (en) * 2018-10-01 2020-04-09 The Trustees Of The University Of Pennsylvania Beta-galactosidase based aav for treating gm1 gangliosidosis
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
CA3177869A1 (en) 2020-05-05 2021-11-11 Duke University Cross-species compatible adeno-associated virus compositions and methods of use thereof

Also Published As

Publication number Publication date
AR122013A1 (es) 2022-08-03
JP7756439B2 (ja) 2025-10-20
US20240067988A1 (en) 2024-02-29
US12037598B2 (en) 2024-07-16
AU2021268946A1 (en) 2022-12-01
TW202208631A (zh) 2022-03-01
EP4125977A4 (en) 2024-09-25
JP2023524291A (ja) 2023-06-09
TWI910162B (zh) 2026-01-01
US12577586B2 (en) 2026-03-17
IL297577A (en) 2022-12-01
EP4125977A2 (en) 2023-02-08
US20230151389A1 (en) 2023-05-18
BR112022022644A2 (pt) 2023-01-17
US20240076695A1 (en) 2024-03-07
CA3177869A1 (en) 2021-11-11
CN116096377A (zh) 2023-05-09
KR20230029616A (ko) 2023-03-03
CN116096377B (zh) 2026-01-02
WO2021226267A2 (en) 2021-11-11
US12146151B2 (en) 2024-11-19
WO2021226267A3 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
PH12020551938A1 (en) Liver targeting adeno-associated viral vectors
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
ZA202105975B (en) Variant aav capsids for intravitreal delivery
PH12019500068A1 (en) Novel adeno-associated virus capsid proteins
WO2020028751A3 (en) Aav variants with enhanced tropism
MX388331B (es) Variantes de virus adenoasociado y métodos de uso de estas
PH12020550094A1 (en) Adeno-associated virus variant capsids and methods of use thereof
MX2024012403A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este
MX2022014256A (es) Redirección del tropismo de las cápsides de aav.
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
MX2020005451A (es) Capsides variantes de virus adenoasociados y uso para inhibir la angiogenesis.
AU2018298422A1 (en) Novel nucleic acid molecules
MX2024009660A (es) Variantes de capside de aav y usos de las mismas.
WO2019210267A3 (en) Engineered aav capsids with increased tropism and aav vectors comprising the engineered capsids and methods of making and using same
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
WO2021025995A9 (en) Aav variants with enhanced tropism
MX2019012223A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
NZ763617A (en) Aav vectors
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
EA201890110A1 (ru) Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения
WO2023004407A3 (en) Adeno-associated virus compositions and methods of use thereof
MX2020002148A (es) Vectores adenoasociados recombinantes.
MX2022004944A (es) Composiciones y metodos para minimizar la perdida de proteinas a concentraciones de proteinas bajas.
EP4223320A3 (en) Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)